Barrington keeps USD 95.00 target for LeMaitre Vascular stock
Published on 10/15/2026 at 18:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target meets calendar
- Barrington analyst Michael Petusky maintained a USD 95.00 target on October 13, 2026.
- LeMaitre Vascular will release third-quarter results on November 4, 2026.
- LeMaitre Vascular stock costs EUR 75.25 at Lang & Schwarz on October 15, 2026 at 6:42 p.m. CEST.
- The price-to-earnings ratio is 29.46 as of October 15, 2026.
LeMaitre Vascular (ISIN US5255582018) has a USD 95.00 analyst target after Barrington analyst Michael Petusky maintained a Buy rating on October 13, 2026. According to Markets Insider, the target lies 13.18 percent above the Nasdaq price of USD 83.94. LeMaitre Vascular stock was trading at EUR 75.25 at Lang & Schwarz on October 15, 2026 at 6:42 p.m. CEST.
Results date brings the next marker
LeMaitre Vascular plans to release third-quarter 2026 financial results on November 4, 2026, after the Nasdaq session. The company also scheduled a conference call for 5:00 p.m. EST that day, according to Yahoo Finance.
Stock sits near its yearly low
At Nasdaq, LMAT stood at USD 83.94 on October 15, 2026 at 12:53 p.m. ET, up 1.60 percent from the prior close. The quote was 7.31 percent above the USD 78.22 52-week low and 28.87 percent below the USD 118.01 high. The current trading volume was 113,814 shares against an average of 326,651 shares.
LeMaitre reported USD 70.38 million in revenue and diluted earnings per share of USD 0.74 for the second quarter of 2026. Revenue increased 9.60 percent from the year-earlier quarter but missed the USD 71.47 million consensus estimate, while earnings per share came in below the USD 0.81 estimate, according to MarketBeat.
Valuation and peer comparison
LeMaitre Vascular had a market capitalization of USD 1.9 billion, a price-to-earnings ratio of 29.46 and a dividend yield of 0.01 percent as of October 15, 2026. Its business centers on medical devices and implants for peripheral vascular disease.
Comparison with peers
LeMaitre Vascular (Nasdaq, USD): plus 1.60 percent, P/E 29.46, market capitalization USD 1.9 billion
Edwards Lifesciences (NYSE, USD): minus 0.31 percent, P/E 49.60, market capitalization USD 49.7 billion
Penumbra (NYSE, USD): plus 0.26 percent, P/E 78.86, market capitalization USD 12.6 billion
Price and investor calendar
The USD 95.00 target gives investors a dated benchmark while the next results date supplies the clearest upcoming company event. The second-quarter figures showed revenue growth, but the reported revenue and earnings per share were below consensus estimates.
LeMaitre Vascular stock was trading at EUR 75.25 at Lang & Schwarz on October 15, 2026 at 6:42 p.m. CEST. The Nasdaq quote was USD 83.94 on October 15, 2026 at 12:53 p.m. ET.
The further course of trading is shown by the continuously updated real-time quote of LeMaitre Vascular stock.
LeMaitre Vascular market data
- Company: LeMaitre Vascular, Inc.
- ISIN: US5255582018
- Ticker: LMAT
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 6:42 p.m. CEST): EUR 75.25
- Market capitalization: USD 1.9 billion (as of October 15, 2026)
- 52-week range: USD 78.22-118.01 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Next earnings date: November 4, 2026
Market context: Market report Nasdaq Composite.
